Introduction
============

In Australia, kidney failure occurs at extremely high rates among Aboriginal and Torres Strait Islander peoples (Indigenous Australians) in remote areas with rates up to 30 times the national average.[@b1] Peritoneal dialysis (PD) has long been an important option for people from remote areas who are on renal replacement therapy (RRT) and wish to return to their home to live and dialyse.

In contrast to international studies,[@b2]--[@b6] recent Australian reports have indicated that patient survival on PD appears to not be as good as patients receiving haemodialysis (HD) therapy,[@b7],[@b8] and outcomes are generally worse when compared with PD patients in other countries.[@b9],[@b10] Peritonitis continues to be a leading cause of technique failure and death for Australian PD patients.[@b8],[@b9],[@b11] From 2002 to 2005, Australia\'s peritonitis rate of an episode every 19.4 patient months was only slightly better than the minimum recommendation of an episode every 18.0 patient months.[@b9],[@b12]

A recent international review concluded that mortality, technique failure and peritonitis rates were generally higher among Indigenous PD patients compared with non-Indigenous patients.[@b13] Locality is also important. Remote Indigenous PD patients have significantly shorter times to first peritonitis, higher technique failureand greater risk of all-cause mortality compared with metropolitan non-Indigenous patients in Australia.[@b14]

What is already known on this subject:

-   There is an epidemic of end-stage kidney disease among Indigenous Australians in remote areas of Australia, and peritoneal dialysis (PD) is an important option for people to return home to live and dialyse.

-   In Australia, peritonitis is the leading cause of technique failure and death, with Indigenous Australian PD patients having a shorter time to first peritonitis and on average nearly twice the number of episodes of peritonitis per year than non-Indigenous patients. Indigenous Australian PD patients from remote locations have a higher risk of peritonitis than metropolitan non-Indigenous patients.

-   Patient and technique survival is inherently biased by initial training, ongoing supervision, retraining and regular contact to detect problems early and avoid later more serious complications

At least 70% of patients originating from the remote Kimberley region received PD early in their treatment.[@b15] Anecdotal evidence suggested that peritonitis and technique failure were common, and duration of PD was limited. Two PD systems have been used: UltraBag (Baxter, Old Toongabbie, NSW, Australia) until 2007 and Stay-Safe (Fresenius Medical Care, Milsons Point, NSW, Australia) starting in 2006. PD patient management and training also changed during 2007 from Royal Perth Hospital (RPH) with training in Perth, to Fresenius Medical Care with training either in Broome at the Kimberly Aboriginal Medical Services Council, or one of two training centres in suburban Perth. It had been suggested locally that increased peritonitis rates occurred following the change in systems. This paper therefore describes outcomes for Kimberley Indigenous Australians receiving PD treatment for the first time comparing them with other Australian PD patients, as well as comparing outcomes in Kimberley patients using the two systems.

Methods
=======

Since 2003, it has been possible to identify and obtain accurate information on all Kimberley patients due to improved local renal services. Kimberley patients were identified based on extensive search and cross-referencing of records, including the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA).[@b15] Patients were retrospectively identified for inclusion in the clinical outcomes and mortality analyses (Fig. [1](#fig01){ref-type="fig"}).

What this study adds:

-   Indigenous Australian PD patients from the Kimberley region had significantly higher recorded rates of technique failure than patients from elsewhere in Australia.

-   For Kimberley patients, there was a significant under-reporting of episodes of peritonitis on The Australia and New Zealand Dialysis and Transplant Registry, and they appear to have nearly double the episodes of peritonitis per patient year than previously reported for Indigenous Australian patients.

-   PD can bring Kimberley patients closer to home, but is relatively short term (median 17-22 months survival across Australia) and can have high levels of morbidity in remote areas. As a result of this study, there has been more caution in recommending PD and concurrently more support for geographically expanded and safer haemodialysis options in the Kimberley.

![Selection process used to determine the Kimberley study populations and the analyses they were included in.](ajr0022-0101-f1){#fig01}

Using only ANZDATA records, we compared outcomes for Kimberley Indigenous PD patients to Indigenous Australian and non-Indigenous patients (≥18 years old) from elsewhere in Australia who had commenced maintenance RRT and PD treatment in Australia for the first time between 1 January 2003 and 31 December 2009. These patients were followed-up until 31 December 2010.

Collection of peritonitis data for Kimberley patients involved an extensive search of local patient, PathWest laboratory, RPH and ANZDATA records. Access to paper records for patients on UltraBag was limited because many patients with peritonitis were managed in Perth during their episodes. The records for some patients who had ceased PD were archived and not possible to access.

The extensive search of patient records identified a further four Kimberley patients not recorded as receiving PD on ANZDATA. To obtain a more accurate time to first peritonitis and to assess potential reporting discrepancies in ANZDATA, we compared peritonitis rates after adding these extra four patients and extra peritonitis information collected on all Kimberley patients. Using these data, we also compared Kimberley patients using UltraBag and those using Stay-Safe. Seven patients who started on UltraBag changed to Stay-Safe during 2006--2007, and for this comparison those patients were censored when they stopped using UltraBag.

Clinical outcomes
-----------------

ANZDATA carries out regular surveys of patients on RRT. Comorbid conditions (diabetes, chronic lung disease, coronary artery disease, peripheral vascular disease, cerebrovascular disease) that were reported to ANZDATA were used to determine comorbid conditions at the start of treatment. Aboriginal or Torres Strait Islander identification was based on ANZDATA records.

We defined technique failure as cessation of PD due to all causes except death, transplantation and recovery of own renal function, consistent with ANZDATA reporting. PD failure and mortality rates are expressed as failures or deaths per 100 patient-years of PD, respectively.

Statistical analysis
--------------------

Differences in baseline characteristics were compared with Kimberley Indigenous patients using χ^2^ test for categorical data, and Mann--Whitney tests for continuous data. Patients were censored for transplantation and recovery of own renal function. To determine median survival on PD patients were also censored for continuing on PD at the end of the study.

Cox proportional hazards ratios (HR) were determined for time to first peritonitis. There was no time group interaction for time to first peritonitis.

As the proportional hazards assumption was violated when assessing technique failure, log-rank test for equality of survivor functions was used to determine significance. Technique failure was also censored for death.

Poisson regression using marginal means was used to adjust death rates per 100 patient-years and Cox proportional hazards to adjust mortality for: age at start of PD, sex, presence of comorbid conditions and PD not the first RRT modality used.

All analyses were performed using Stata, version 13 (StataCorp, College Station, Texas, USA). Point estimates were presented with 95% CIs; *P* \< 0.05 was considered statistically significant.

Ethics approval
---------------

Ethics approval was obtained from the Human Research Ethics Committee of The University of Western Australia and the Western Australian Aboriginal Health Information and Ethics Committee.

Results
=======

A snapshot of the modality and location of Kimberley Indigenous patients receiving RRT is shown in Table [1](#tbl1){ref-type="table"}. The demographic and baseline data for Australian patients recorded on ANZDATA are shown in Table [2](#tbl2){ref-type="table"}.

###### 

Annual snapshot (at 31 December each year) of modality/location of Kimberley Indigenous RRT patients

  Modality/Location                                2003   2004   2005   2006   2007   2008   2009   2010
  ------------------------------------------------ ------ ------ ------ ------ ------ ------ ------ ------
  Home therapies                                                                                    
   Peritoneal dialysis                             23     19     19     16     17     24     18     10
   Home haemodialysis                              5      4      5      6      5      3      6      5
   Transplantation                                 6      5      5      5      6      9      10     13
  Haemodialysis (HD)                                                                                
   Kimberley[†](#tf1-1){ref-type="table-fn"}       33     37     39     43     44     43     42     45
   non-Kimberley[‡](#tf1-2){ref-type="table-fn"}   11     20     17     23     29     33     33     34
  Total                                            78     85     85     93     101    112    109    107

HD treatment in the Kimberley is provided by the Kimberley Satellite Dialysis Centre (10 chairs, up to 41 patients) in Broome and Derby Aboriginal Health Service (two chairs, up to eight patients) in Derby;

HD treatment outside the Kimberley is mainly provided in Perth, and 25 patients were on waiting lists to have therapy provided in the Kimberley at 31 December 2010. RRT, Renal replacement Therapy.

###### 

Demographic characteristics and baseline data of Australian patients ≥ 18 years old who commenced PD and RRT for the first time from 1 January 2003 to 31 December 2009

                                          Indigenous Australians                                                  
  --------------------------------------- ------------------------ ---------------------------------------------- ---------------------------------------------------
  No. of patients                         71                       384                                            5285
  Median age at start of first PD (IQR)   52.4 (44.8-61.7)         53.1 (45.6-61.4)                               63.8 (51.1-73.1)[\*](#tf2-1){ref-type="table-fn"}
  Female (%)                              49 (69.0%)               204 (53.1%)[\*](#tf2-1){ref-type="table-fn"}   2195 (41.5%)[\*](#tf2-1){ref-type="table-fn"}
  PD not first RRT modality used (%)      17 (23.9%)               186 (48.4%)[\*](#tf2-1){ref-type="table-fn"}   1834 (34.7%)
  Comorbid conditions                                                                                             
   Diabetes (%)                           56 (78.9%)               300 (78.1%)                                    2050 (38.8%)[\*](#tf2-1){ref-type="table-fn"}
   Chronic lung disease (%)               11 (15.5%)               72 (18.8%)                                     795 (15.0%)
   Coronary heart disease (%)             30 (42.3%)               189 (49.2%)                                    1979 (37.5%)
   Peripheral vascular disease (%)        25 (35.2%)               127 (33.1%)                                    1244 (23.5%)[\*](#tf2-1){ref-type="table-fn"}
   Cerebrovascular disease (%)            7 (9.9%)                 62 (16.2%)                                     766 (14.5%)

PD = peritoneal dialysis. RRT = Renal replacement Therapy. IQR = Interquartile range.

Significant at *P* \< 0.05 compared with the group of Kimberley Indigenous patients.

Kaplan--Meier survival estimates for time to first peritonitis as recorded on ANZDATA are shown in Figure [2](#fig02){ref-type="fig"}a. As shown in Table [3](#tbl3){ref-type="table"}, both groups of Indigenous PD patients had significantly shorter times to first peritonitis and median survival, and higher technique failure than non-Indigenous patients. While Indigenous patients from the Kimberley and elsewhere had similar time to first peritonitis, patients from the Kimberley had significantly higher technique failure than those from elsewhere in Australia (Table [3](#tbl3){ref-type="table"}).

![Kaplan--Meier survival estimates to first peritonitis during first peritoneal dialysis (PD) treatment. (a) Kimberley Indigenous patients and Indigenous and non-Indigenous patients from elsewhere in Australia (\**P* \< 0.001 compared with the group of non-Indigenous Australian patients) () non-Indigenous (*n* = 5285); () Indigenous -- rest of Australia (*n* = 384)\*; () Indigenous -- Kimeberley (*n* = 71)\*; (b) Kimberley Indigenous patients on the two PD systems used in Kimberley. Patients were ≥18 years old, commenced PD for the first time in Australia from 1 January 2003 to 31 December 2009 and followed up until 31 December 2010. () Baxter UltraBag (*n* = 32); () Fresenius Medicare Stay--Safe (*n* = 43).](ajr0022-0101-f2){#fig02}

###### 

Clinical outcomes during first PD treatment of patients ≥18 years old who commenced PD and RRT for the first time in Australia from 1 January 2003 to 31 December 2009. Patients were followed up until 31 December 2010

                                                                                                     Indigenous Australians                                                                                    
  -------------------------------------------------------------------------------------------------- --------------------------------------------------- ----------------------------------------------------- ------------------
  Patient-years                                                                                      113.1                                               645.7                                                 9182.4
  Median time on PD during first PD treatment in months (IQR)                                        17.3 (10.0-26.8)                                    17.5 (7.4-29.1)                                       16.9 (7.6-29.3)
  Median survival on PD during first PD treatment in months (IQR)[\#](#tf3-3){ref-type="table-fn"}   17.5 (10.0-29.3)[\*](#tf3-1){ref-type="table-fn"}   19.8 (7.9-33.6)[\*](#tf3-1){ref-type="table-fn"}      22.5 (9.1-44.5)
  Median time (months) to first peritonitis (IQR)                                                    11.2 (4.5-18.0)[\*](#tf3-1){ref-type="table-fn"}    12.5 (4.1-25.7)[\*](#tf3-1){ref-type="table-fn"}      21.5 (8.2-44.6)
  Peritonitis hazard ratio (95% CI)                                                                                                                                                                            
   Crude                                                                                             2.0 (1.6-2.7)[\*](#tf3-1){ref-type="table-fn"}      1.7 (1.5-1.9)[\*](#tf3-1){ref-type="table-fn"}        1.00
   Adjusted[†](#tf3-4){ref-type="table-fn"}                                                          2.0 (1.5-2.6)[\*](#tf3-1){ref-type="table-fn"}      1.6 (1.4-1.8)[\*](#tf3-1){ref-type="table-fn"}        1.00
  Technique failure (95% CI) rate per 100 patient-years[‡](#tf3-5){ref-type="table-fn"}              46.0 (35.0-60.3)[\*](#tf3-1){ref-type="table-fn"}   31.3 (27.3-35.9)[\*\*](#tf3-2){ref-type="table-fn"}   25.2 (24.2-26.2)
  Mortality (95% CI)                                                                                                                                                                                           
   Crude                                                                                                                                                                                                       
    Death rate per 100 patient-years                                                                 11.5 (6.7-19.8)                                     16.3 (13.4-19.7)[\*\*](#tf3-2){ref-type="table-fn"}   12.8 (12.1-13.6)
    Hazard ratio                                                                                     0.96 (0.56-1.66)                                    1.28 (1.05-1.57)[\*\*](#tf3-2){ref-type="table-fn"}   1.00
   Adjusted[†](#tf3-4){ref-type="table-fn"}                                                                                                                                                                    
    Death rate per 100 patient-years[§](#tf3-6){ref-type="table-fn"}                                 16.0 (8.0-24.0)                                     19.4 (15.8-23.1)[\*](#tf3-1){ref-type="table-fn"}     13.5 (12.7-14.2)
    Hazard ratio[¶](#tf3-7){ref-type="table-fn"}                                                     1.31 (0.76-2.29)                                    1.49 (1.20-1.84)[\*](#tf3-1){ref-type="table-fn"}     1.00

Significant at *P* \< 0.001 and

significant at *P* \< 0.05 compared with the group of non-Indigenous Australian patients.

Censored for continuing on PD at the end of the study, transplantation and recovery of own renal function.

In the final Cox proportional hazards model the characteristics significantly (at *P* ≤ 0.05) associated with earlier time of first peritonitis are diabetes (HR, 1.13 (95% CI, 1.05-1.22)); and cardiovascular disease (HR, 1.12 (95% CI, 1.01-1.24)) and PD not the first RRT modality used (HR, 1.17 (95% CI, 1.09-1.27)).

Censored for death, transplantation and recovery of own renal function. Log-rank test for equality of survivor functions was used to determine significance.

Means for the covariates for the Poisson regression of adjusted death rate: age 60.4 years; 57.4% male; 41.9% with diabetes; 15.3% with chronic lung disease; 38.3% with coronary heart disease; 24.3% with peripheral vascular disease; 14.5% with cerebrovascular disease; and 35.5% PD not the first RRT modality used.

In the final Cox proportional hazards model the characteristics significantly (at *P* ≤ 0.05) associated with mortality are age (HR, 1.04 (95% CI, 1.04-1.05); female (HR, 0.86 (95% CI, 0.77-0.97)); diabetes (HR, 1.37 (95% CI, 1.22-1.54)); chronic lung disease (HR, 1.33 (95% CI, 1.17-1.52)); coronary heart disease (HR, 1.43 (95% CI, 1.26-1.62)); peripheral vascular disease (HR, 1.50 (95% CI, 1.32-1.70)); cerebrovascular disease (HR, 1.17 (95% CI, 1.02-1.34)); and PD not the first RRT modality used (HR, 1.53 (95% CI, 1.37-1.71)). CI, confidence interval; HR, Hazard ratio; IQR, interquartile range; PD, peritoneal dialysis; RRT, renal replacement therapy.

Based on ANZDATA records adjusted mortality rates and hazard ratios of Indigenous PD patients located elsewhere were significantly worse than non-Indigenous patients; however, there was no significant difference between Kimberley patients and non-Indigenous patients (Table [3](#tbl3){ref-type="table"}). Adding the extra four Kimberley patients to the ANZDATA information did not alter this result.

We then assessed whether the high peritonitis and technique failure rate of Kimberley patients was associated with the change in PD systems. Thirty-two and 43 patients contributed 48.1 and 57.0 patient-years on UltraBag and Stay-Safe, respectively. Kaplan--Meier survival estimates to first peritonitis are shown in Figure [2](#fig02){ref-type="fig"}b. The median time to first peritonitis was 9.0 (IQR 4.6--12.5) and 6.1 (IQR 1.7--14.8) months for patients on UltraBag and Stay-Safe, respectively. Overall, there was no significant difference in risk (HR 1.2 (95% CI, 0.72-1.95); *P* = 0.508), with an average of 2.0 episodes of peritonitis per patient year. One patient had nine episodes over 15 months.

Based on our audit of files in addition to ANZDATA information, we found that 13 (9 UltraBag, 4 Stay-Safe) of the 67 (19.4%) first episodes of peritonitis were not recorded in ANZDATA. Other discrepancies included 11 (three UltraBag, eight Stay-Safe) later episodes that were recorded in ANZDATA as first episodes, and six (one UltraBag, five Stay-Safe) first episodes recorded in ANZDATA did not match episodes recorded in patient notes. After adding the extra information on peritonitis, the median time to first peritonitis for Kimberley patients was reduced to 8.4 (IQR 3.1--13.8) from 11.2 (IQR 4.5--18.0) months.

Seven patients were switched from UltraBag to Stay-Safe. Five (71%) patients had peritonitis within 45 days of changing from UltraBag to Stay-Safe, five failed within nine months due to peritonitis, and three died within 11 months of the change while on PD.

Discussion
==========

Kimberley Indigenous patients had significantly higher recorded rates of technique failure and shorter time to first peritonitis than non-Indigenous PD patients. There also appear to have been more episodes of peritonitis per patient year than previousl reported for Indigenous patients (2.0 versus 1.15).[@b16] For Kimberley patients, there was also significant under-reporting of episodes of peritonitis on ANZDATA. Whether similar under-reporting occurs elsewhere in Australia is unknown.

Despite more than three times the number of episodes of peritonitis than previously reported for Australian PD patients (2.0 versus 0.6),[@b17] median survival on PD for Kimberley patients was only five months shorter than non-Indigenous patients (17.5 versus 22.4 months). This was much lower than Canadian patients (Aboriginal: 40.1, non-Aboriginal: 45.5 months), although this study did not take into account changes in modality.[@b18] Consistent with previous reports, adjusted mortality rates for Indigenous PD patients from elsewhere in Australia were also significantly higher than non-Indigenous patients.[@b13],[@b14],[@b16] The mortality rates for Kimberley patients fell between these two groups.

There are a number of factors that impact on patient outcomes on PD, including patient selection, prophylaxis and timely treatment of infectious complications, social factors, patient education and support and clinical governance and professional standards.[@b9] These are likely to be particularly relevant for those living in remote areas such as the Kimberley region, where reduced access to resources, health literacy discrepancies relevant to PD education and training, access to medical and nursing care, high turnover of staff, adherence to treatment protocols as well as socioeconomic disadvantage, are likely to play a role.[@b13]

In this population, there were few patients who, from a clinical perspective, had good outcomes on PD. However, patients may have a different view. For some a year at home on PD, even with episodes of peritonitis, may be preferred to having HD with less morbidity in Perth. A few patients appeared to do very well on PD. Unfortunately, we could not find reliable predictors to identify patients likely to have better outcomes on PD.

While patients using the Stay-Safe system did tend to have earlier first episodes of peritonitis, there were no statistical difference overall between the two systems. In addition despite our best efforts, there could have been greater undercounting of peritonitis in early (Ultrabag) as against later years of the study (Stay-Safe) due to more difficulty accessing medical records as described in the methods. More undercounting on the 'Ultrabag' system than on the Stay-Safe system may explain some of the non-statistically significant difference between the systems.

Despite no clear difference between systems overall, for the seven patients who changed system, three deaths and a trend to more and earlier post-conversion peritonitis episodes is concerning. We recommend extreme caution in the future before changing a patient from one PD system to another in this population.

Kimberley PD patients had higher adjusted death rates per 100 patient-years (16.0, 95% CI; 8.0--24.0) compared with an earlier study (2003--2007) of HD patients (10.2, 95% CI; 6.6--15.7).[@b15] While these differences are not statistically significant, and these were different studies over different time periods, it raises concerns that mortality may be worse on PD than HD for Kimberley patients, as is seen in general in Australia (HR 1.10; 95% CI:1.06--1.16).[@b7]

Peritoneal dialysis continues to be a useful therapy; however, the demonstrated significantly increased morbidity, and a potential increase in mortality highlights some of the risks. At the time of the study, Kimberley patients accounted for 14.8% of the Indigenous PD person-years in Australia (see Table [3](#tbl3){ref-type="table"}), while in the HD study, the Kimberley patients only accounted for 8.1% of Indigenous person-years on HD.[@b15] This demonstrates very high levels of use of PD relative to HD for Kimberley patients at the time, due presumably to limited alternatives for patients on RRT to return closer to home. As a result of the experience reported in this study, there has been more caution in recommending PD in this population. Fortunately other options are expanding, with satellite HD now available in four Kimberley towns, and 'home' HD is provided effectively in secure clinic rooms in several locations.

PD remains an important therapy for suitable remote patients to get closer to home if they are fully informed of the risks. PD can bring Kimberley patients closer to home; however in Australia, it is relatively short term for most patients and potentially hazardous. Further work to improve the delivery of PD in the Kimberley and Australia more generally is required if use of this modality is to be expanded. The current and future expansion of safer haemodialysis options closer to home in the Kimberley is required to ensure long-term culturally safe care can be provided to all people who require RRT.
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